Citadel Advisors
CRDL

Citadel Advisors’s Cardiol Therapeutics CRDL Stock Holding History

Citadel Advisors’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,700
Closed -$1.65K – 12870
2025
Q1 		$1.65K Sell
1,700
-2,100
-55% -$2.58K ﹤0.01% 14117
2024
Q4 		$4.86K Sell
3,800
-5,700
-60% -$9.61K ﹤0.01% 13898
2024
Q3 		$18.8K Buy
9,500
+2,100
+28% +$4.36K ﹤0.01% 12821
2024
Q2 		$14.9K Buy
+7,400
New +$15.7K ﹤0.01% 12855
2024
Q1 		– Sell
-1,000
Closed -$840 – 14659
2023
Q4 		$840 Buy
+1,000
New +$850 ﹤0.01% 13929
2023
Q1 		– Sell
-1,600
Closed -$816 – 14815
2022
Q4 		$816 Buy
+1,600
New +$975 ﹤0.01% 14578
2022
Q2 		– Sell
-30,500
Closed -$47K – 13009
2022
Q1 		$47K Sell
30,500
-40,200
-57% -$66.3K ﹤0.01% 12828
2021
Q4 		$131K Buy
+70,700
New +$195K ﹤0.01% 12434

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors's CRDL Position: Q1 2026 in Review

Citadel Advisors opened a new position in Cardiol Therapeutics (CRDL) in Q1 2026: 819,904 shares worth $1.11M. The stake represents ﹤0.01% of the portfolio and ranks #7440 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CRDL as recently as Q3 2025.

Citadel Advisors first reported a position in CRDL in Q4 2021 and has held it in 12 quarters since. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Citadel Advisors held 819,904 shares of Cardiol Therapeutics worth $1.11M as of Q1 2026.
  • Cardiol Therapeutics was a new Citadel Advisors position in Q1 2026.
  • Cardiol Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7440 holding.
  • Citadel Advisors first reported a position in Cardiol Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.